AbCellera Biologics Inc.

NasdaqGS:ABCL

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🤖 Artificial Intelligence (AI)

📊 Big Data

🧬 Biotechnology

Location

Canada

Market Cap

USD 1.12 B

Share Price

USD 3.61

Avg Daily Volume

4,033,461

Change (1 day)

-3.48%

Change (1 year)

25.35%

Change (YTD)

23.21%

AbCellera Biologics Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending March 31, 2025: 295,629,655

AbCellera Biologics Inc. Shares (Diluted, Weighted) is 295,629,655 for the Trailing 12 Months (TTM) ending March 31, 2025, a 1.84% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

AbCellera Biologics Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending March 31, 2024 was 290,293,152, a -2.39% change year over year.
AbCellera Biologics Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending March 31, 2023 was 297,392,259, a 4.21% change year over year.
AbCellera Biologics Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending March 31, 2022 was 285,386,411, a -0.24% change year over year.
AbCellera Biologics Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending March 31, 2021 was 286,060,280.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Shares (Diluted, Weighted)	Selling, General, and Administrative Expenses (SG&A)	Research and Development (R&D) Expenses	Revenue

NasdaqGS: ABCL

AbCellera Biologics Inc.

CEO	Dr. Carl L.G. Hansen Ph.D.
IPO Date	Dec. 11, 2020
Location	Canada
Headquarters	2215 Yukon Street
Employees	596
Sector	🏥 Health Care
Industries Clinical Trials 🤖 Artificial Intelligence (AI) 📊 Big Data 🧬 Biotechnology

Description

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.